BIO4 Campus Belgrade: 1.000+ PhDs and 300+ Labs

BIO4 Campus Belgrade:
1.000+ PhDs and 300+ Labs

BIO4 Campus Belgrade:
1.000+ PhDs and 300+ Labs

Support for investments in biotechnology, innovation


Prime Minister Ana Brnabic spoke today with representatives of the South Korean company SK bioscience, which specialises in the development and production of vaccines and other biological medications, about the establishment of cooperation and the possibility of Serbia becoming their centre for production, research and development, i.e., serving as a hub for Europe.

SK is the second largest conglomerate of the Republic of Korea, and this high-level visit marks the beginning of the implementation of the Memorandum of Understanding, which the Prime Minister signed in Seoul on 8 September with the companies SK bioscience and Frontier Pharma.

These companies are considering the possibility of significant joint investment, especially due to research and development opportunities, which are opened by the construction of the BIO4 Campus in the field of biomedicine, biotechnology, bioinformatics and biodiversity. Frontier Pharma is also the owner of the company Zdravlje from Leskovac.

Brnabic said during the meeting that the Government of Serbia is committed to the development of innovations and that their project is welcome in Serbia, for which they will have full support.

She pointed out the importance our country attaches to European integration, and assessed that products registered in our country will be recognized in the European Union when Serbia becomes its full member.

The Prime Minister stated that biotechnology is the future and that is why she insists on discussions and consultations with experts in that field, because Serbia's intention is to become one of the world's most attractive destinations for investments in this field.

CEO of SK bioscience Jaeyong Ahn said that the employees of that company are ready to transfer their rich experience to their colleagues in Serbia.

During the meeting, it was also mentioned that Serbia has already demonstrated itself as a credible partner, possesses very good technology, and therefore, there is readiness to collaborate with Serbian companies on researching the new generation of vaccines and other advanced therapies.


Share This Story, Choose Your Platform!

Go to Top